The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Levin O.S.

Russian Medical Academy of Continuous Professional Education

Voznyuk I.A.

Pavlov First Saint Petersburg State Medical University;
Immanuel Kant Baltic Federal University

Illarioshkin S.N.

Research Center of Neurology

Tkacheva O.N.

Pirogov Russian National Research Medical University

Bogolepova A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies

Vasenina E.E.

Russian Gerontological Scientific and Clinical Center of Pirogov Russian National Research Medical University

Gavrilova S.I.

Mental Health Research Centre

Dokukina T.V.

Republican Scientific and Practical Center of Mental Health

Emelin A.Y.

Kirov Military Medical Academy

Lobzin V.Y.

Kirov Military Medical Academy;
Mechnikov North-Western State Medical University

Mkhitaryan E.A.

Research Center of Neurology

Khatkova S.E.

National Medical Research Center «Treatment and Rehabilitation Center»

Yakushin M.A.

Moscow Regional Research and Clinical Institute;
Semashko National Research Institute of Public Health

Yanishevsky S.N.

Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation

Cognitive impairment and tactics of using the drug Cerebrolysin. Resolution of the International Council of Experts (May 12, 2023)

Authors:

Levin O.S., Voznyuk I.A., Illarioshkin S.N., Tkacheva O.N., Bogolepova A.N., Vasenina E.E., Gavrilova S.I., Dokukina T.V., Emelin A.Y., Lobzin V.Y., Mkhitaryan E.A., Khatkova S.E., Yakushin M.A., Yanishevsky S.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(9): 121‑130

DOI: 10.17116/jnevro2023123091121

Read: 8046 times

Download PDF (RU)
Contact the author
Table of contents

COGNITIVE IMPAIRMENT AND TACTICS OF USING THE DRUG CEREBROLYSIN. RESOLUTION OF THE INTERNATIONAL COUNCIL OF EXPERTS (MAY 12, 2023)
COGNITIVE IMPAIRMENT AND TACTICS OF USING THE DRUG CEREBROLYSIN. RESOLUTION OF THE INTERNATIONAL COUNCIL OF EXPERTS (MAY 12, 2023)

To cite this article:

Levin OS, Voznyuk IA, Illarioshkin SN, et al. . Cognitive impairment and tactics of using the drug Cerebrolysin. Resolution of the International Council of Experts (May 12, 2023). S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(9):121‑130. (In Russ.)
https://doi.org/10.17116/jnevro2023123091121

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16
Nutritional care for patients with neurodegenerative diseases in the outpatient practice of a neurologist. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):76-83
The expe­rience of diagnosing Alzheimer’s disease based on the study of cere­brospinal fluid biomarkers. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):91-97
Neurobiological pote­ntial of astragaloside IV and prospects for its use in the treatment of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):7-12
Cere­brolysin and the opti­mal timing of anti­coagulation resu­mption in stroke: combined post hoc survival analysis of the CERE­HETIS trial. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):77-93
Comparative study of cognitive impairment in subgroups of bipo­lar affe­ctive diso­rder types I and II, occu­rring with and without psychotic symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):7-11
Rela­tionship between stroke-associated pneumonia and long-term outcomes of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):57-61
Pote­ntial of animal-derived neuropeptides in complex therapy of diabetic neuropathy in patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):83-87
Cyto­kine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12
Study of the levo­carnitine effi­cacy for the treatment of mode­rate cognitive impairment in patients with hype­rtension. Russian Journal of Preventive Medi­cine. 2025;(4):45-50
Abstract:

The aging of the population and the associated increase in the share of cognitive impairments in the structure of a wide range of diseases are a serious challenge for modern healthcare. Difficulties in the treatment of cognitive disorders are determined by many factors, including the age of patients, comorbidity, forced polypragmasia and the adequacy of the dosage of drugs that restore cognitive activity. The experts discussed information about the therapeutic potential of the drug Cerebrolysin in the treatment of cognitive disorders of various origins, stated significant experience of its effective and safe use in many clinical studies in mild and moderate forms of dementia. At the same time, there was a lack of consistent and systematic data on the dosage regimen, frequency, and duration of use of the drug in different forms of cognitive impairment and the degree of their severity. The aim of the international council of experts was to determine the optimal dosage regimens of the drug Cerebrolysin in patients with various etiologies and severity of cognitive impairment. The result of the work was the approval of a unified scheme for the use of the drug Cerebrolysin, considering the severity of the disease and its duration.

Keywords:

cognitive impairment
dementia
Alzheimer’s disease
nootropic drugs
Cerebrolysin

Authors:

Levin O.S.

Russian Medical Academy of Continuous Professional Education

Voznyuk I.A.

Pavlov First Saint Petersburg State Medical University;
Immanuel Kant Baltic Federal University

Illarioshkin S.N.

Research Center of Neurology

Tkacheva O.N.

Pirogov Russian National Research Medical University

Bogolepova A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies

Vasenina E.E.

Russian Gerontological Scientific and Clinical Center of Pirogov Russian National Research Medical University

Gavrilova S.I.

Mental Health Research Centre

Dokukina T.V.

Republican Scientific and Practical Center of Mental Health

Emelin A.Y.

Kirov Military Medical Academy

Lobzin V.Y.

Kirov Military Medical Academy;
Mechnikov North-Western State Medical University

Mkhitaryan E.A.

Research Center of Neurology

Khatkova S.E.

National Medical Research Center «Treatment and Rehabilitation Center»

Yakushin M.A.

Moscow Regional Research and Clinical Institute;
Semashko National Research Institute of Public Health

Yanishevsky S.N.

Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation

Received:

15.08.2023

Accepted:

15.08.2023

Close metadata

References:

  1. World Health Organization (WHO) [Electronic resource]. 10.07.2023. (In Russ.). https://www.who.int/news-room/fact-sheets/detail/dementia
  2. Levin OS. Diagnostika i lechenie kognitivnykh narushenii i dementsii v klinicheskoi praktike. M.: Medpressinform; 2021. (In Russ.).
  3. Zakharov VV. Kognitivnye rasstroistva bez dementsii: klassifikatsiya, osnovnye prichiny i lechenie. Effektivnaya Farmakoterapiya. 2016;1:22-31. (In Russ.).
  4. Clinical guidlines of the Ministry of Health of the Russian Federation «Cognitive disorders in the elderly and senile age» 2020. (In Russ.). https://psyrus.ru/med_psy/klinicheskie-rekomendatsii/kognitivnie_rasstroistva_pogilie_1204202.pdf
  5. Goldemund D, Telecká S. Kognitivní poruchy u pacientů s cévním onemocněním mozku. Psychiatrie Pro Praxi. 2008;9(3):125-128. 
  6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
  7. Chen N, Yang M, Guo J, et al. Cerebrolysin for vascular dementia. Cochrane Database of Systematic Reviews. 2013;(1):CD008900. https://doi.org/10.1002/14651858.CD008900.pub2
  8. Cui S, Chen N, Yang M, et al. Cerebrolysin for vascular dementia. Cochrane Database of Systematic Reviews. 2019;2019(11):CD008900. https://doi.org/10.1002/14651858.CD008900.pub3
  9. Chukanova EI. Sravnitel’nyi analiz effektivnosti Tserebrolizina pri lechenii patsientov s khronicheskoi ishemiei mozga. Farmakoekonomicheskie aspekty. Trudnyi Patsient. 2011;9(1):32-37. (In Russ.).
  10. Chukanova EI. Tserebrolizin v lechenii patsientov s sindromom myagkogo kognitivnogo snizheniya. Trudnyi Patsient. 2008;6(2-3):32-35. (In Russ.).
  11. Anisimova AV, Kolesnikova TI, Iutskova EV, Galkin SS, Zimin IA. Neiroprotektivnaya terapiya pri lechenii khronicheskoi tserebrovaskulyarnoi patologii, vliyanie na gemoreologicheskie i morfodensitometricheskie pokazateli krovi. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2014;114(10):72-80. (In Russ.).
  12. Fedin AI, Generalov VO, Mishnyakova LP, et al. Dinamika kognitivnykh funktsii u bol’nykh s khronicheskoi ishemiei golovnogo mozga na fone parenteral’nogo primeneniya tserebrolizina. Trudnyi Patsient. 2008;6(12):51-54. (In Russ.).
  13. Maximova MYu, Timerbaeva SL, Smirnova IN. Preventing of cognitive disorders progression in patients with cerebrovascular diseases. Trudnyi Patsient. 2011;9(6):23-29. (In Russ.).
  14. Gavrilova SI, Fyodorov YaB, Kolykhalov IV, et al. The therapeutic potential of Cerebrolysin in the preventive therapy of Alzheimer’s disease. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2008;108(8):24-29. (In Russ.).
  15. Gavrilova SI, Kolykhalov IV, Fedorova IaB, et al. Possibilities of preventive treatment of Alzheimer’s disease: results of the 3-year open prospective comparative study on efficacy and safety of the course therapy with Cerebrolysin and Cavinton in elderly patients with the syndrome of mild cognitive impairment. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2010;110(1):62-69. (In Russ.).
  16. Damulin IV, Mkhitaryan EA, Koberskaya NN. Cerebrolysin treatment of mild cognitive impairment of vascular genesis. Terapevticheskii Arkhiv. 2007;79(6):65-69. (In Russ.).
  17. Gordeeva IE, Ansarov KhSh, Sokolova VYu. Effektivnost’ tserebrolizina pri khronicheskoi ishemii golovnogo mozga. Effektivnaya Farmakoterapiya. 2018;(1):6-8. (In Russ.).
  18. Gordeeva IE, Ansarov KSh, Sokolova VI. The role of neurotrophic therapy in the treatment of cognitive disorders caused by diabetes mellitus. Consilium Medicum. 2020;22(2):35-40. (In Russ.).
  19. Malashenkova IK, Krynskiy SA, Hailov DP, et al. Anti-inflammatory effects of neurotrophic therapy (a pilot study). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(5):39-44. (In Russ.). https://doi.org/10.17116/jnevro20181185139
  20. Boksha IS, Gavrilova SI, Kolykhalov IV, et al. Progression of Cognitive Deficit in Older People with Mild Cognitive Impairment Treated with Cerebrolysin. Health. 2014;6:2581-2591. https://doi.org/10.4236/health.2014.619297
  21. Suvorova IA. Efficacy of prolonged course of Cerebrolysin therapy in poststroke dementia. Sibirskii Meditsinskii Zhurnal (Irkutsk). 2009;90(7):66-70. (In Russ.).
  22. Muresanu DF, Alvarez XA, Moessler H, et al. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study. Journal of the Neurological Sciences. 2010;299(1-2):179-183.  https://doi.org/10.1016/j.jns.2010.08.040
  23. Guekht AB, Moessler H, Novak PH, Gusev EI; Cerebrolysin Investigators. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. Journal of Stroke and Cerebrovascular Diseases. 2011;20(4):310-318.  https://doi.org/10.1016/j.jstrokecerebrovasdis.2010.01.012
  24. Tapu M, Bicu D, Tapu F, Stovicek O. The efficacy of cerebrolysin in vascular dementia. Journal of the Neurological Sciences. 2009;283(1):286.  https://doi.org/10.1016/j.jns.2009.02.177
  25. Lobzin VYu, Emelin AYu, Odinak MM, et al. Value of determining the cerebrospinal fluid protein markers of amyloidosis and neurodegeneration in the diagnosis of vascular and neurodegenerative cognitive impairments. Neurology, Neuropsychiatry, Psychosomatics. 2013;4:21-27. (In Russ.). https://doi.org/10.14412/2074-2711-2013-2450
  26. Sharma S, Raj K, Singh S. Protective effects of cerebrolysin against chemotherapy (car-mustine) induced cognitive impairment in Albino mice. Drug and Chemical Toxicology. 2022;45(6):2769-2779. https://doi.org/10.1080/01480545.2021.1991195
  27. Gauthier S, Proano JV, Jia J, et al. Cerebrolysin in mild-to-moderate Alzheimer’s disease: a meta-analysis of randomized controlled clinical trials. Dementia and Geriatric Cognitive Disorders. 2015;39(5-6):332-347. 
  28. Instructions for the medical use of the drug Cerebrolysin, RU P N013827/01, update from 01/24/2022. (In Russ.).
  29. Nevrologiya. Natsional’noe rukovodstvo. Pod red. Guseva E.I., Konovalova A.N., Skvortsovoi V.I., Gekht A.B. M.: GEOTAR-Media; 2018. (In Russ.).
  30. Programma profilaktiki, rannego vyyavleniya, diagnostiki i lecheniya kognitivnykh rasstroistv u lits pozhilogo i starcheskogo vozrasta: Metodicheskie rekomendatsii. Pod red. Tkachevoi O.N. M.: Prometei, 2019. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.